Comparison Between Effect of Glimepiride and Pioglitazone on the C-Reactive Protein Level of Type 2 Diabetic Patient

Authors

  • AKM Fazlul Haque Medical Officer, Asthma Centre, NIDCH, Mohakhali, Dhaka
  • Md Zahirul Haque Assistant Professor of Medicine, Rajshahi Medical College
  • ARM Saifuddin Ekram Professor of Medicine, Rajshahi Medical College
  • M Azizul Hoque Associate Professor of Medicine, Rajshahi Medical College
  • Quazi Tarikul Islam Professor of Medicine, Dhaka Medical College

DOI:

https://doi.org/10.3329/jom.v12i1.6929

Keywords:

Type-2 diabetes, hs-CRP, Glimepiride, Pioglitazone, Cardiovascular complication

Abstract

Background: This study was carried out to see the effect of glimepiride and pioglitazone on the serum hs-CRP level in type 2 diabetic patients.

Material and Methods: A non-blind comparative study was conducted among 70 patients with type 2 diabetes (as per WHO criteria) divided into two groups (35 each) to see the effect of glimepiride and pioglitazone on their blood hs-CRP level.

Results: 35 type-2 diabetic patients were given glimepiride. Another 35 patients were given pioglitazone. Fasting blood sugar, HbA1c%, hs-CRP and lipid profile were estimated before and 12 weeks after intervention. The mean change of serum hs-CRP was 1.13 mg/L to 0.76 mg/L in pioglitazone group. In glimepiride group the mean change of serum hs-CRP was 0.96 mg/L to 0.94 mg/L after 12 weeks. The change was greater in pioglitazone group in comparison to glimepiride group.

Conclusion: Reduction of hs-CRP was significant in the study subjects revealing its future potential in reducing the vascular complications of type - 2 diabetes mellitus.

Keyword: Type-2 diabetes; hs-CRP; Glimepiride; Pioglitazone; Cardiovascular complication

DOI: 10.3329/jom.v12i1.6929

J Medicine 2011; 12 : 30-33

Downloads

Download data is not yet available.
Abstract
704
PDF
531

Downloads

How to Cite

Haque, A. F., Haque, M. Z., Ekram, A. S., Hoque, M. A., & Islam, Q. T. (2011). Comparison Between Effect of Glimepiride and Pioglitazone on the C-Reactive Protein Level of Type 2 Diabetic Patient. Journal of Medicine, 12(1), 30–33. https://doi.org/10.3329/jom.v12i1.6929

Issue

Section

Original Articles